Tillman Pearce

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

William D. Tap, Zsuzsanna Pápai, Brian A. Van Tine et al. · The Lancet Oncology · 2017 · 306 citations · Full text

Medicine, Oncology, Pharmacology +12

Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

Walter Reinisch, W de Villiers, László Bene et al. · Inflammatory Bowel Diseases · 2009 · 220 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa

Bruno François, Charles‐Édouard Luyt, Anthony Dugard et al. · Critical Care Medicine · 2012 · 182 citations

Medicine, Pharmacokinetics, Pharmacology +17

Convergence of evolving artificial intelligence and machine learning techniques in precision oncology

Elena Fountzilas, Tillman Pearce, Mehmet A. Baysal et al. · npj Digital Medicine · 2025 · 153 citations · Full text

Medicine, Cancer Biology, Oncology +16

Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia

R T Dorr, Chatchada Karanes, Catherine Spier et al. · Journal of Clinical Oncology · 2001 · 82 citations

Medicine, Oncology, Pharmacology +17